Poolbeg Pharma (POLB) has received Clinical Trial Authorisation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its POLB 001 TOPICAL trial, while independent US payer research points to a multi-billion-dollar peak sales opportunity.
The authorisation clears the final regulatory hurdle for the study, with site initiation visits scheduled and interim data expected this summer. Meanwhile, the company said the trial is progressing as planned across six UK sites.
POLB 001 is being developed as a potential preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome (CRS). The TOPICAL trial will enrol about 30 relapsed or refractory multiple myeloma patients receiving the approved bispecific antibody teclistamab, supplied by Johnson & Johnson at no cost.
The study now includes NHS Lothian in Edinburgh and Royal Stoke University Hospital, alongside existing sites at The Christie, The Royal Marsden, University College London Hospitals, and University Hospitals Birmingham. Patient screening is expected to begin shortly. The acute nature of CRS means the trial design supports a relatively rapid readout.
Notably, independent research conducted by Acumetis Global, covering payers representing about 75 million lives across commercial insurance, Medicare and Medicaid, highlighted a strong value proposition for POLB 001. The findings suggest the therapy could reduce hospitalisation costs and enable a shift in care from specialist centres to outpatient settings.
The report also noted that CRS occurs in most CAR T and bispecific antibody treatments, with no established way to predict its onset or severity. As a result, treatment delays and discontinuations are common, increasing both clinical risk and cost burden.
The research reaffirmed that an effective preventative therapy could deliver significant economic and clinical benefits, with pricing analysis indicating multi-billion-dollar peak sales potential in the United States. Consequently, the findings strengthen confidence in POLB 001’s commercial outlook and its appeal to potential partners.
Poolbeg Pharma’s Chief Executive Officer Jeremy Skillington said: “We have made excellent progress on the TOPICAL clinical trial, with all regulatory approvals now received, additional trial sites added to the study, and site initiation visits scheduled, we are on track to achieve interim data this summer. We believe POLB 001 has the potential to transform the cancer immunotherapy field through the prevention of CRS, improving patient quality of life and expanding the number of patients that can receive these life-saving cancer immunotherapies.
“In addition, the findings from the independent research report offer important external validation of both the clinical relevance and commercial opportunity of POLB 001. The clear willingness for payers to address the significant burden associated with CRS, reinforces our confidence in POLB 001's ability to deliver meaningful value to healthcare systems and its potential to achieve multi-billion-dollar peak sales in the US.”
View from Vox
Regulatory clearance for the TOPICAL trial marks a key de-risking step for Poolbeg, with near-term interim data now in sight. Meanwhile, the independent payer research adds commercial weight, highlighting a sizeable and well-defined market opportunity if POLB 001 can demonstrate efficacy.